Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

Abstract Chimeric antigen receptor (CAR) T‐cell therapy is an immunotherapy approach that has played a tremendous role in the battle against cancer for years. Since the CAR T lymphocytes are unrestricted‐major histocompatibility complex T lymphocytes, they could identify more targets than natural T cells, resulting in practical and widespread functions. The good prospects of CAR T‐cell therapy in oncology can be additionally applied to treat other diseases such as autoimmune and infectious diseases. CAR‐T cell‐derived immunotherapy for autoimmune disorders can be allocated to CAR‐Tregs and chimeric autoantibody receptor T cells. Other generations of CARs target human immunodeficiency virus (HIV) proteins. In this review, we summarize CAR‐T cell therapies in autoimmune disorders and HIV infection.